Sepsis
Conditions
Interventions
Sepsis group:An additional 5-10ml of blood was collected on the day, day 2, and day 7 of the diagnosis of sepsis (Hospitalized patients with sepsis).
Control group:An additional 5-10ml of blood was collected during physical examination.
Sponsors
Department of Burns and Cutaneous Surgery, the First Affiliated Hospital of Air Force Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Sepsis group inclusion criteria: 1. Patients with clinically confirmed Sepsis (Sepsis 3.0 criteria, jointly published by the American Society of Critical Care Medicine (SCCM) and the European Society of Critical Care Medicine (ESICM)) 2. Between the ages of 18 and 70, regardless of gender Inclusion criteria of healthy control group: 1. No chronic or infectious diseases, and in good health. 2. Between the ages of 18 and 70, regardless of gender.
Exclusion criteria
Exclusion criteria: 1. Patients receiving known immunomodulatory drugs (thymosin, transfer factor, pidotimod, gamma globulin, etc.); 2. Patients with immune dysfunction, HIV infection, or patients who have been treated with radiation, hormones (systemic), chemotherapy, growth factors and immunosuppressive drugs within 1 month; 3. Subjects who are considered by the researcher to have a serious disease (such as malignant tumor, etc.) that may affect the study; 4. Patients with contraindications to anticoagulant drugs; 5. Absolute IgA deficiency; 6. Pregnant women or other researchers assessed that they were not suitable to participate in the study; 7. Patients hospitalized for sepsis within 3 months prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phagocytic function of macrophages;Phenotype of macrophages;Macrophage metabolomics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Acid phosphatase of macrophages;Procoagulant activity of macrophages;Macrophage transcriptomics;C reactive protein;Procalcitonin;Blood amyloid protein;ferritin;Heparin binding protein;Interleukin-6;Interleukin-10;Tumor necrosis factor-alpha; | — |
Countries
China
Contacts
Public ContactYang Xuekang
Department of Burns and Cutaneous Surgery, the First Affiliated Hospital of Air Force Military Medical University
Outcome results
None listed